Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20396182 | 1.00 | MGLL (0.40) | MGLLGPR119CYP2D6CYP1A2TSHR | |
| SCHEMBL20396110 | 0.92 | MGLL (0.41) | MGLLGPR119CYP2D6CYP1A2TSHR | |
| SCHEMBL20396109 | 0.92 | MGLL (0.41) | MGLLGPR119CYP2D6CYP1A2TSHR | |
| SCHEMBL20396040 | 0.89 | MGLL (0.39) | MGLLGPR119CYP2D6CYP1A2TSHR | |
| SCHEMBL20396039 | 0.89 | MGLL (0.39) | MGLLGPR119CYP2D6CYP1A2TSHR | |
| SCHEMBL18418314 | 0.87 | MGLL (0.43) | MGLL | |
| SCHEMBL18422323 | 0.87 | MGLL (0.43) | MGLL | |
| SCHEMBL18422804 | 0.84 | ALDH1A1 (0.41) | MGLLCYP2D6CYP1A2TSHRCYP3A4 | |
| SCHEMBL18422808 | 0.84 | ALDH1A1 (0.41) | MGLLCYP2D6CYP1A2TSHRCYP3A4 | |
| SCHEMBL18422207 | 0.84 | CYP3A4 (0.43) | MGLLCYP1A2CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10626125-B2 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as MAGL inhibitors | PFIZER INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-20190276472-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | PFIZER INC. (US) | 2019-09-12 | — | — | US | disclosed |
| US-10329308-B2 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as MAGL inhibitors | PFIZER INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20180208607-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | PFIZER INC. (US) | 2018-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190276472-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | MAG, PYM1, HIF1AN | MGLL 18/4885GPR119 748/4885CYP2D6 1155/4885 |
| US-10626125-B2 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as MAGL inhibitors | MAG, PYM1, HIF1AN | MGLL 18/4885GPR119 748/4885CYP2D6 1155/4885 |
| US-20180208607-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | MAG, PYM1, HIF1AN | MGLL 18/4885GPR119 748/4885CYP2D6 1155/4885 |
| US-10329308-B2 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as MAGL inhibitors | MAG, PYM1, HIF1AN | MGLL 18/4885GPR119 748/4885CYP2D6 1155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.